comparemela.com
Home
Live Updates
Takeda Intends to Rapidly Initiate the First Global Phase 3
Takeda Intends to Rapidly Initiate the First Global Phase 3
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK861 an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024
Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.
Related Keywords
Japan ,
United States ,
Osaka ,
Japanese ,
Yuko Yoneyama ,
Takeda Pharmaceutical Company Limited ,
Exchange Commission ,
Upcoming Scientific Congress ,
Key Secondary Endpoints Were Met ,
Narcolepsy Type ,
Generally Safe ,
Results Will ,
Upcoming Scientific ,
Wakefulness Test ,
Annual Report ,
Media Contact ,
Takeda Tak861 Orexin Receptor 2 Ox2r Narcolepsy Type 1 Nct05687903 Nct05687916 Nt1 Nt2 Maintenance Of Wakefulness Test Epworth Sleepiness Scale Weekly Cataplexy Rate Sarah Sheikh Gastrointestinal Inflammation Rare Diseases Plasmaderived Therapies Oncology Neuroscience Vaccines ,